Current stage -Stage IV Page 2 Posts on Medivizor
Navigation Menu

Current stage -Stage IV Posts on Medivizor

Looking for men with high-risk prostate cancer features after prostate surgery to trial a type of radiation therapy

Posted by on Apr 17, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of radiation therapy, in treating patients with high-risk prostate cancer features after radical prostatectomy (surgery to remove the prostate gland). The main outcome to be measured will be freedom from failure. Failure is evidence that the cancer has returned. Patients will be followed up for 5...

Read More

Looking for men with newly diagnosed advanced prostate cancer to test treatment combinations

Posted by on Mar 28, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of radical prostatectomy, in newly diagnosed advanced prostate cancer. The main outcome to be measured will be survival without the cancer worsening. This trial is recruiting in the United States. The details Androgens can cause the growth of prostate cancer cells. Antiandrogen therapy (ADT) may...

Read More

Evaluating a radionuclide treatment for metastatic castration-resistant prostate cancer

Posted by on Mar 26, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness of a radionuclide (RN), [¹??Lu]-PSMA-617, to treat metastatic castration-resistant prostate cancer (mCRPC) that has worsened after standard treatments. They found that this treatment was safe and effective for these patients. Some background Prostate cancer (PC) affects the...

Read More

Looking for men with prostate cancer, resistant to male hormone suppression, to be treated with medication and radiotherapy

Posted by on Jan 20, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluates the effectiveness of medication and focal radiation in the treatment of prostate cancer resistant male hormone suppression. The main outcome to be measured in this trial is the number of patients whose cancer does not grow or spread and who are alive at 18 months after treatment. This trial is taking place in Ann...

Read More

Searching for patients with castration resistant metastatic prostate cancer to test cabazitaxel and abiraterone

Posted by on Dec 10, 2018 in Prostate cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of cabazitaxel (Jevtana) with abiraterone acetate (Zytiga) compared to abiraterone acetate alone for metastatic (cancer that has spread) castration-resistant prostate cancer (cancer that is no longer responding to hormone therapy). The main outcome measured will be the...

Read More

Can prednisone be replaced with dexamethasone in patients with prostate cancer treated with abiraterone acetate?

Posted by on Sep 29, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the use of dexamethasone, instead of prednisone, used with abiraterone acetate (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC). This study found that prednisone to dexamethasone switch can benefit some patients with mCRPC. Some background Androgen deprivation therapy...

Read More

Evaluating cabazitaxel in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 6, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effectiveness of cabazitaxel used for patients with metastatic castration-resistant prostate cancer. This study found that patients treated with cabazitaxel had maintained or improved quality of life and pain control. Some background One treatment option for prostate cancer is androgen deprivation...

Read More

Does age matter? Enzalutamide or bicalutamide for mestastatic castration-resistant prostate cancer patients of different ages

Posted by on Feb 12, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...

Read More

Looking for men with castration-resistant prostate cancer to test ipatasertib plus abiraterone/prednisone

Posted by on Dec 5, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...

Read More